A Fully Human Monoclonal Antibody with Novel Binding Epitope and Excellent Neutralizing Activity to Multiple Human IFN-α Subtypes: a Candidate Therapy for Systemic Lupus Erythematosus

Du P, et al., 7(5):969-80, MAbs, 2015

This article introduces a neutralizing antibody named AIA22 which consist of an alternate epitope and a different neutralizing profile to those observed in anti interferon alpha (IFN-α) antibodies currently in clinical trials. IFN-α protein plays a central role in the pathogenesis of systemic lupus erythematosus (SLE). A series of competitive binding assays were carried out using an Octet QKe system in order to identify AIA22 binding region on the IFN-α. The Octet QKe system equipped with anti-human-IgG (AHC) biosensors was used to capture purified AIA22 followed by monitoring of its binding with IFN-α2b.

Read More